Doyon Won is an associate in Nutter’s Intellectual Property Department. With his deep knowledge in life science technologies, Doyon counsels clients on drafting and prosecuting patent applications and strategic portfolio management in a broad range of technology areas, including:
- Small molecule drugs
- Oligonucleotide therapeutics
- Medical devices
During law school, Doyon worked at The George Washington University’s Technology Commercialization Office, where he assisted in the University’s technology commercialization efforts. Prior to pursuing a career in law, Doyon held various positions in the pharmaceutical and financial sectors after completing his Ph.D in pathobiology.
In addition to his intellectual property work, Doyon is committed to the firm’s proud legacy of pro bono representation. In collaboration with Kids in Need of Defense (KIND), Doyon works to help secure lawful permanent residency for children who had been neglected and abandoned in their home country.
To view Doyon’s LinkedIn profile, please click here.
News & Insights
- Patents or Trade Secrets? Deciding How Best to Protect Your Invention Part II: Business ConsiderationsIP Law Bulletin, 02.20.2018
- Patents or Trade Secrets? Deciding How Best to Protect Your Invention Part I: Can The Invention be Kept Secret?IP Law Bulletin, 10.10.2017
- IP Law Bulletin, 05.15.2017
- IP Law Bulletin, 04.11.2017
- A Report on The World’s Most Innovative Universities Affirms Strengths of Massachusetts Universities and Others Around the WorldIP Law Bulletin, 12.13.2016
- SCOTUS UPSETS THE APPLE CART?: The High Court Answers Key Question on Design Patent Damages, But Leaves Many UnansweredIP Law Bulletin, 12.06.2016
Education & Admissions
The George Washington University Law School, J.D.
University of Toronto, Ph.D., Laboratory Medicine & Pathobiology
University of Toronto, B.Sc., Human Biology
- U.S. Court of Appeals for the Federal Circuit
- U.S. District Court for the District of Massachusetts
- U.S. Patent and Trademark Office (Limited recognition to practice under 37 CFR § 11.9(b))
Before law school, Doyon prepared new drug application submissions as a regulatory affairs associate at a Canadian pharmaceutical company and advised startups as an associate at a boutique investment bank.
Doyon completed his Ph.D. in laboratory medicine and pathobiology where his research focused on endothelial cell mechanotransduction in early stages of atherosclerosis.